MARK2 and ovarian cancer: PIM2, a serine/threonine kinase, has been shown to be highly expressed in many cancers, including breast cancer 22, liver cancer 28, stomach cancer 29, lymph cancer 30, ovarian cancer 31, endometrial cancer 16, prostate cancer 32, and lung cancer 33.